Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.

Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Droździk M.

Eur J Clin Pharmacol. 2010 Jul;66(7):681-7. doi: 10.1007/s00228-010-0818-1. Epub 2010 Apr 8.

PMID:
20376628
2.

Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.

Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M.

Eur J Clin Pharmacol. 2006 Oct;62(10):877-80. Epub 2006 Aug 16.

PMID:
16912869
3.

Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.

Oh JH, Dong MS, Choi MG, Yoo HW, Lee SB, Park YI, Chung IS.

J Gastroenterol Hepatol. 2009 Feb;24(2):294-8. doi: 10.1111/j.1440-1746.2008.05605.x. Epub 2008 Sep 24.

PMID:
18823430
4.

Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.

Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9. Epub 2005 Jun 23.

PMID:
15976989
5.

Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.

Karaca RO, Kalkisim S, Altinbas A, Kilincalp S, Yuksel I, Goktas MT, Yasar U, Bozkurt A, Babaoglu MO.

Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):199-206. doi: 10.1111/bcpt.12667. Epub 2016 Nov 2.

6.
7.

Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.

Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K.

Clin Gastroenterol Hepatol. 2004 Jan;2(1):22-30.

PMID:
15017629
8.

Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.

Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, Song IS, Jung HC.

J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1287-91. doi: 10.1111/j.1440-1746.2008.05392.x. Epub 2008 Jul 10.

PMID:
18637061
10.

Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.

Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, Osato MS, El-Zimaity HM, Davis KD, Graham DY; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group.

Helicobacter. 2003 Dec;8(6):626-42. Erratum in: Helicobacter. 2004 Apr;9(2):183.

PMID:
14632678
11.

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.

J Gastroenterol Hepatol. 2002 Jul;17(7):748-53.

PMID:
12121503
12.

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.

Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.

Am J Gastroenterol. 2003 Nov;98(11):2403-8.

PMID:
14638340
13.

The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.

Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-Forti G, Miglioli M, Biagi GL, Paolini M.

Am J Gastroenterol. 2003 May;98(5):1010-5.

PMID:
12809821
14.

High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.

Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.

PMID:
14696516
15.

Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.

Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A.

Aliment Pharmacol Ther. 2007 Sep 1;26(5):693-703.

16.

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.

Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K.

Clin Pharmacol Ther. 1999 Nov;66(5):528-34.

PMID:
10579481
17.

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.

Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM.

Korean J Gastroenterol. 2003 Dec;42(6):468-75.

18.

Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.

Prasertpetmanee S, Mahachai V, Vilaichone RK.

Helicobacter. 2013 Aug;18(4):270-3. doi: 10.1111/hel.12041. Epub 2013 Jan 29.

PMID:
23356886
19.

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.

Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH.

Pharmacotherapy. 2011 Mar;31(3):227-38. doi: 10.1592/phco.31.3.227.

PMID:
21361732
20.

Supplemental Content

Support Center